# Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab

> **NCT06498622** · PHASE2 · RECRUITING · sponsor: **Anhui Provincial Hospital** · enrollment: 45 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Donafenib + Envafolimab

## Key facts

- **NCT ID:** NCT06498622
- **Lead sponsor:** Anhui Provincial Hospital
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-20
- **Primary completion:** 2027-05-20
- **Final completion:** 2027-05-20
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2024-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06498622

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06498622, "Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With Envafolimab". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06498622. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*